Zila Nutraceuticals Establishes Scientific Advisory Board; Leading Researchers and Clinicians to Advise Company
January 11 2006 - 8:30AM
Business Wire
Zila, Inc.'s, (Nasdaq: ZILA) wholly owned subsidiary, Zila
Nutraceuticals, Inc., manufacturer of Ester-C(R) and Ester-E(R),
has established a Scientific Advisory Board to provide scientific
advice and guidance to the company. Larry Robinson, PhD, Zila's
Vice President of Scientific Affairs stated, "We are excited that
this panel of internationally recognized nutrition and health
experts will be working with us to help direct our nutraceutical
research, development and marketing initiatives." Previously
conducted research suggests that both Ester-C(R) and Ester-E(R) may
be more proactive in helping to maintain healthy immune and
cardiovascular function due to their particular and unique
proprietary properties. "We look forward to working with these
respected researchers and clinicians as we further our clinical
research efforts," said Dr. Robinson. "They will be an important
part of our team and offer the opportunity for Zila to effectively
supplement the research already available or soon to be published
on our line of patented 'Ester' products," he added. Advisory Board
Members are, in alphabetical order: Vern S. Cherewatenko, MD, MEd,
founder of HealthMax Incorporated, a medical wellness company,
founder of the 'Cares For America' program that provides medical
services for patients who then volunteer time at a charitable
organization to pay off their bill, and a founder of the American
Association of Patients and Providers, Inc., a non-profit
organization to promote changes in healthcare that are
wellness-focused and promote patient choice. Dr. Cherewatenko is
the author of a number of patient education programs, doctor
education programs, has written two books: The Diabetes Cure and
The Stress Cure. Mohsen Meydani, DVM, PhD, Director of Vascular
Biology Program and Senior Scientist at Tufts University's Jean
Mayer USDA Human Nutrition Research Center on Aging. Dr. Meydani's
research focuses on the role of dietary antioxidants, lipids and
oxidative stress on molecular mechanisms of immune/endothelial
cells interaction in atherogenesis and angiogenesis. Dr. Meydani
has published more than 150 scientific original and review
articles. Mark Moyad, MD, MPH. Dr. Moyad occupies an endowed
position created and funded entirely by his patients. He is the
Phil F. Jenkins Director of Preventive & Alternative Medicine
at the University of Michigan Medical Center (Department of
Urology). The primary author of over 80 medical articles, Dr. Moyad
is the editor-in-chief of the soon to be released medical journal
"Seminars in Preventive & Alternative Medicine" by Elsevier. He
is an editor or regular reviewer for numerous medical journals
including British Journal of Urology, Cancer, European Urology,
International Journal of Cancer, Lancet, Journal of Urology,
Nutrition and Cancer, Urology and others. About Ester-C(R) Ester-C
is an advanced form of vitamin C that is pH neutral, providing a
form that is easily tolerated by the body. During the patented
process of producing Ester-C, the ascorbic acid undergoes changes
similar to those that occur in the body, which results in vitamin C
metabolites. It is the only vitamin C that contains these
metabolites, which help it work differently than regular vitamin C.
Ester-C has also been clinically proven to remain active in the
immune system for 24 hours. About Ester-E(R) Ester-E is an advanced
form of vitamin E containing d-alpha tocopheryl phosphates (or "TP"
for short). Until recently, scientists were unaware of this
important source of vitamin E in the body. Research suggests that
the human body may convert other forms of vitamin E into TP in
order to protect the vitamin's antioxidant strength until the body
is ready to use it. Scientists are now able to replicate this
natural form of vitamin E by joining a phosphate molecule to
natural vitamin E in a patented process, preserving vitamin E's
natural health benefits until the body is ready to use it.
Therefore, Ester-E is protected until it is needed, rather than
being used up prematurely. These statements have not been evaluated
by the Food and Drug Administration. This product is not intended
to diagnose, treat, cure or prevent any disease. Visit
www.Ester-E.com or www.Ester-C.com for more information about the
"Ester" line of premium products. About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is an innovator in preventative
healthcare technologies and products, focusing on enhanced body
defense and the detection of pre-disease states. Zila has three
business units: -- Zila Biotechnology, a research, development and
licensing business specializing in pre-cancer/cancer detection
through its patented Zila(R) Tolonium Chloride and OraTest(R)
technologies. -- Zila Pharmaceuticals, marketer of products to
promote oral health and prevent oral disease, including ViziLite(R)
Plus oral examination kits and Peridex(R) prescription periodontal
rinse. -- Zila Nutraceuticals, manufacturer and marketer of
Ester-C(R) and Ester-E(R), branded, highly effective forms of
Advanced Protection vitamins C and E. -- For more information about
Zila, visit www.zila.com. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2005.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024